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ABSTRACT- The records of 21 patients who had radical cystectomies for the treatment of locally 
advanced bladder cancer and were found to have regional lymphatic metastases have been re- 
viewed. Ten of these patients had only one lymph node involved (Nl), and 11 patients had metas- 
tases in more than one lymph node (N2-3). Four patients with Nl disease and 1 patient with N2-3 
disease survived tumor-fTee greater than forty months postoperatively. Radical cystectomy can pro- 
duce long-term disease-free survival in some patients with limited pelvic metastases. 
The treatment of high-stage locally advanced 
bladder cancer is often radical cystectomy with 
urinary diversion. Despite a variety of pre- 
operative imaging techniques, understaging oc- 
curs in more than 33 per cent of patients.’ This 
is frequently a result of failure to detect small- 
volume regional lymphatic metastases. The 
overall survival of patients with lymphatic me- 
tastases is low. However, it has been reported 
that an aggressive lymph node dissection may 
be associated with improved survival2 We have 
evaluated our experience with 21 patients who 
have undergone a therapeutic radical cystec- 
tomy and were found to have metastases in re- 
gional lymph nodes. 
Material and Methods 
The records of 21 patients who had radical 
cystectomies performed for therapeutic intent 
and were found to have regional lymphatic me- 
tastases were reviewed. A bilateral pelvic 
lymphadenectomy was performed starting at 
the bifurcation of the common iliac vessels and 
extending along the external and internal iliac 
chains. These patients have had their operative 
procedures performed by multiple attending 
and resident surgeons at the University of Mi- 
chigan Medical Center. Similarly, the patho- 
logic material was evaluated by a number of 
different attending and resident pathologists. 
As a result of this, there was not a uniform tech- 
nique applied to either the performance of the 
surgery or the subsequent analysis of the surgi- 
cal specimens. This situation, we believe, is a 
reflection of the diversity of surgical and patho- 
logic practice that exists in the United States. 
The patients have been followed from two to 
fifty-eight months. The lymph node staging is 
that of the American Joint Committee on Can- 
cer. 3 Ten patients had lymphatic metastasis con- 
fined to one lymph node. Eleven patients had 
metastases in more than one lymph node. No 
one has been lost to follow-up. Statistical analy- 
sis of the data (survival curves) was performed 
using the Cox model of survival analysis with 
covariates by the BMDP statistical software 
package from the University of California. The 
Fisher exact test was used for analysis as 
described here. 
Results 
The mean ages and number of patients sur- 
viving greater than forty months in each group 
are listed in Table I. Of the patients with only 
one metastatic lymph node (Nl), 4 patients are 
still alive at two, forty-four, forty-five, and 
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TABLE I. Patient characteristics 
Stage 




Nl 10 61.7 4 (40%) 
N2-3 11 67.1 1 (9%) 
fifty-eight months. All of these individuals are 
currently free of disease. Furthermore, the 1 
patient who survived greater than forty months 
but subsequently died at forty-five months was 
free of neoplasm at the time of his death. Only 1 
patient with more than one metastatic lymph 
node (N2-3) has survived beyond forty months 
(44 months). This patient had three perivesical 
lymph nodes involved by metastases and is cur- 
rently disease-free. 
The age adjusted survival curves are shown 
in Figure 1 and demonstrate a survival advan- 
tage for the group with only one metastatic 
lymph node. Although there is a calculated 71 
per cent increase in the death rate in the group 
with more than one lymph node, the data do 
not reach statistical significance (p = 0.36). 
Seventy-five patients would be required in each 
group to reliably detect a statistically signifi- 
cant difference in these two groups with the 
same survival difference! The Fisher exact test 
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TABLE II. Survival status at forty months 
Stage Alive, Disease-Free Dead 
Nl 4 5 
N2-3 1 10 
was used to assess the statistical significance be- 
tween the groups of patients who were disease- 
free and alive forty months after surgery (Table 
II). This excluded the 1 patient in the Nl group 
who is alive at two months. The probability of 
the data occurring by chance using the Fisher 
exact test is 0.0975. 
Comment 
The role of surgery in the treatment of meta- 
static disease remains controversial. At the very 
least, lymphadenectomy serves a staging role to 
differentiate between patients with favorable 
and unfavorable prognoses. At best, aggressive 
local treatment with excision of regional metas- 
tases may produce surgical cures of high-stage 
lesions. There exists a large number of clinical 
reports attesting to the limited success of this 
approach.4-e However, there is a suggestion that 
in certain instances surgical treatment of meta- 
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FIGURE 1. Age adjusted survival. A = patients with metastasis to one lymph 
node; B = patients with metastases to more than one lymph node. 
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this phenomenon in urologic oncology are seen 
in carcinomas of the testis and penis.‘18 The role 
of surgery in advanced bladder cancer is less 
clear. However, aggressive surgical therapy of 
distant metastases has occasionally resulted in 
long-term tumor-free survival.9,10 
Most reports document poor five-year sur- 
vival in patients with regional lymphatic metas- 
tases at the time of cystectomy. The five-year 
survival of these patients has generally been re- 
ported to be 15 per cent or less. Furthermore, 
most of these patients die within thirty months 
of their surgical procedure. An example is the 
large series of Smith and Whitmore” in which 5 
of 30 patients (17%) with Nl disease survived 
five years free of disease while only 5 per cent 
(4/79) patients with Stage N2-3 shared a simi- 
larly favorable course. Dretler, Ragsdale, and 
Leadbetter12 reported on the five-year survival 
rates of 35 patients with regional lymphatic me- 
tastases who had been treated by cystectomy. 
Patients with metastases to one or two lymph 
nodes survived longer than patients with 
greater than two lymphatic metastases. The re- 
spective survival for the two groups was 33 and 
9 per cent. In 1982, Skinner2 reported the effect 
of a “meticulous” lymph node dissection on pa- 
tient survival in a group of patients with re- 
gional lymphatic metastases. Thirty-six patients 
with regional lymphatic metastases had a six- 
year survival of 35 per cent. Patients with five 
or fewer involved lymph nodes had a better sur- 
vival than patients with more diffuse involve- 
ment. The survival in these two groups was 46 
per cent and 12 per cent, respectively. The im- 
provement in survival in more recent series does 
not appear to be an artifact of decreased mor- 
tality from a general improvement in patient 
care. McCarron and Marshall6 demonstrated 
that patients with regional lymphatic metas- 
tases shared a similar fate regardless of the time 
of their surgery. The five-year survival for pa- 
tients treated from 1926 to 1952 and a similar 
group treated from 1960 to 1971 had five-year 
survivals of 4 and 9 per cent, respectively. 
We have found a significant clinical advan- 
tage in the survival of patients with limited re- 
gional lymphatic metastasis. The age adjusted 
three-year survival in the patients with one 
node and in patients with more than one lymph 
node involved by me&static bladder cancer was 
45 per cent and 20 per cent, respectively. Al- 
though continuing follow-up will be required to 
be certain that there are no late failures, no pa- 
tient to date who has survived forty months has 
had recurrence of their disease. Four patients 
are alive and disease-free beyond this point. 
Three have had one lymph node involved with 
neoplasm and one had metastases in three 
perivesical lymph nodes. This clinical improve- 
ment in survival cannot yet be demonstrated to 
be statistically significant. Maintaining the cur- 
rent survival advantage would require approxi- 
mately 130 more patients to document a statis- 
tically significant difference between the Nl 
and N2-3 survival curves at the 0.05 level. 
Our series of patients undergoing radical cys- 
tectomy and having regional lymphatic metas- 
tasis confirms the findings of Skinner2 that some 
patients can have long-term, disease-free sur- 
vival after this therapy. The effect of the sur- 
geon and pathologist in determining the extent 
of the lymph node dissection and the complete- 
ness of the histologic examination on long-term, 
tumor-free survival remains undefined. Al- 
though these variables may influence the re- 
ported results, the available data strongly sug- 
gest that radical cystectomy should be 
performed when surgically resectable pelvic 
lymphatic metastases are found. 
Ann Arbor, Michigan 48109 
(DR. GROSSMAN) 
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